Retinitis (Cytomegalovirus - HHV-5)

Overview

Plain-Language Overview

Cytomegalovirus (CMV) retinitis is an eye infection that affects the retina, the light-sensitive tissue at the back of the eye responsible for vision. It is caused by the cytomegalovirus, a common virus that usually remains dormant but can reactivate in people with weakened immune systems. This condition primarily affects individuals with HIV/AIDS or those on immunosuppressive therapy. The infection leads to inflammation and damage of the retina, causing symptoms like blurred vision, floaters, and potential vision loss. If untreated, it can result in permanent blindness due to retinal scarring and detachment.

Clinical Definition

Retinitis caused by cytomegalovirus (CMV), also known as CMV retinitis, is a sight-threatening opportunistic infection predominantly seen in immunocompromised patients, especially those with advanced HIV/AIDS or post-transplant immunosuppression. The disease is characterized by viral replication within retinal cells, leading to necrotizing retinitis with associated hemorrhages and retinal whitening. CMV, a member of the Herpesviridae family (HHV-5), causes direct cytopathic effects and induces an inflammatory response that damages retinal tissue. Clinically, it presents with progressive visual impairment, floaters, and scotomata. Without prompt antiviral treatment, CMV retinitis can cause retinal detachment and irreversible vision loss, making early recognition and management critical.

Inciting Event

Reactivation of latent CMV infection in retinal tissue due to profound immunosuppression.
Primary CMV infection in congenital cases leading to early retinal involvement.
Immunosuppressive treatments triggering loss of CMV immune control.
HIV-induced depletion of CD4+ T cells allowing viral replication.

Latency Period

CMV retinitis typically develops weeks to months after onset of severe immunosuppression.
In congenital infection, retinal disease may present within the first few months of life.
Post-transplant CMV retinitis usually occurs 1 to 6 months after transplantation.
Latency varies depending on degree and duration of immune compromise.

Diagnostic Delay

Early symptoms are often subtle or nonspecific, leading to delayed recognition.
Lack of routine ophthalmologic screening in high-risk patients delays diagnosis.
Misattribution of visual symptoms to other opportunistic infections or medication side effects.
Limited access to specialized fundoscopic examination or retinal imaging in some settings.

Clinical Presentation

Signs & Symptoms

Painless progressive vision loss is the hallmark symptom
Floaters and photopsia may be reported
Visual field defects correspond to areas of retinal necrosis
Decreased visual acuity often progresses rapidly without treatment
No significant ocular pain differentiates from other infectious retinitides

History of Present Illness

Patients report painless, progressive visual loss often starting unilaterally.
Symptoms include floaters, scotomas, and blurred vision developing over days to weeks.
Visual field defects correspond to areas of retinal necrosis and inflammation.
In advanced cases, patients may notice peripheral vision loss or complete blindness.

Past Medical History

History of HIV/AIDS with low CD4 counts or recent decline in immune status.
Prior organ or stem cell transplantation with ongoing immunosuppression.
Use of immunosuppressive drugs such as corticosteroids or chemotherapy.
Previous diagnosis of CMV viremia or systemic CMV disease.

Family History

No significant familial inheritance pattern is associated with CMV retinitis.
Family history may reveal hereditary immunodeficiency syndromes increasing susceptibility.
Congenital CMV infection risk may be influenced by maternal CMV serostatus but not familial genetics.
No known familial syndromes directly linked to increased CMV retinitis risk.

Physical Exam Findings

Retinal hemorrhages and cotton wool spots visible on fundoscopic exam
Yellow-white granular retinal lesions with areas of necrosis and edema
Vitreous inflammation causing hazy media and decreased red reflex
Retinal detachment may be observed in advanced cases
Optic disc edema can be present in severe inflammation

Diagnostic Workup

Diagnostic Criteria

Diagnosis is established by characteristic fundoscopic findings of areas of retinal whitening with associated hemorrhages and granular borders, often described as a 'pizza pie' or 'cottage cheese with ketchup' appearance. Confirmation is supported by detection of CMV DNA via PCR in ocular fluid or blood. The presence of immunosuppression, especially low CD4 counts (<50 cells/mm³) in HIV patients, supports the diagnosis. Fluorescein angiography may show areas of retinal ischemia, and clinical correlation with symptoms such as visual disturbances is essential.

Pathophysiology

Key Mechanisms

Reactivation of latent cytomegalovirus (CMV) in retinal cells causes direct viral cytopathic effects and necrotizing retinitis.
Immunosuppression impairs cytotoxic T-cell control of CMV, allowing unchecked viral replication in retinal tissue.
CMV infection induces inflammatory cytokine release leading to retinal edema, hemorrhage, and necrosis.
Progressive destruction of retinal layers results in visual field defects and potential retinal detachment.
CMV encodes proteins that inhibit host immune responses, facilitating persistent infection.

Involvement	Details
Organs	Eye is the organ affected by cytomegalovirus retinitis, with involvement of the retina causing visual impairment.
Organs	Immune system status critically influences susceptibility to cytomegalovirus retinitis, especially in immunocompromised hosts.
Tissues	Retinal tissue is the primary site of infection and inflammation in cytomegalovirus retinitis, leading to vision loss.
Tissues	Choroidal tissue may be involved secondarily due to inflammation and vascular compromise during retinitis.
Cells	Retinal pigment epithelial cells are the primary site of cytomegalovirus infection and viral replication in retinitis.
	T lymphocytes play a critical role in controlling cytomegalovirus infection and preventing progression of retinitis.
	Macrophages contribute to local inflammation and tissue damage during active viral retinitis.
Chemical Mediators	Interferon-gamma is important for antiviral immune response and control of cytomegalovirus replication in retinal tissue.
Chemical Mediators	Tumor necrosis factor-alpha mediates inflammation and contributes to retinal tissue damage in active retinitis.

Treatments

Pharmacological Treatments

Ganciclovir
- Mechanism:
  - Inhibits viral DNA polymerase, preventing viral DNA synthesis in cytomegalovirus-infected cells.
- Side effects:
  - Bone marrow suppression
  - Neutropenia
  - Renal toxicity
- Clinical role:
  - First-line
Foscarnet
- Mechanism:
  - Directly inhibits viral DNA polymerase by binding to the pyrophosphate binding site, blocking viral DNA elongation.
- Side effects:
  - Nephrotoxicity
  - Electrolyte imbalances
  - Seizures
- Clinical role:
  - Second-line
Cidofovir
- Mechanism:
  - Nucleotide analogue that inhibits viral DNA polymerase, leading to chain termination during viral replication.
- Side effects:
  - Nephrotoxicity
  - Neutropenia
  - Ocular hypotony
- Clinical role:
  - Second-line

Non-pharmacological Treatments

Regular ophthalmologic monitoring with fundoscopic examination to assess disease progression and treatment response.
Management of underlying immunosuppression, including initiation or optimization of antiretroviral therapy in HIV patients.

Prevention

Pharmacological Prevention

Ganciclovir or valganciclovir prophylaxis in high-risk immunocompromised patients
Foscarnet or cidofovir as alternative antiviral prophylaxis
Maintenance antiviral therapy to prevent CMV reactivation in AIDS patients
Preemptive therapy guided by CMV viral load monitoring
Antiretroviral therapy (ART) to restore immune function and reduce CMV risk

Non-pharmacological Prevention

Regular ophthalmologic screening for early detection in high-risk patients
Strict adherence to ART to maintain immune competence in HIV/AIDS
Avoidance of excessive immunosuppression when possible in transplant recipients
Safe blood transfusion practices to reduce CMV transmission
Patient education on symptom awareness for prompt ophthalmologic evaluation

Outcome & Complications

Complications

Retinal detachment due to necrosis and vitreoretinal traction
Permanent vision loss from extensive retinal damage
Secondary glaucoma from inflammatory debris obstructing aqueous outflow
Optic neuropathy from adjacent inflammation
Endophthalmitis in rare cases of severe intraocular infection

Short-term Sequelae	Long-term Sequelae
Rapid progression of retinal necrosis leading to acute vision decline Vitreous inflammation causing floaters and visual haze Macular edema impairing central vision Retinal hemorrhages contributing to visual disturbances Transient ocular pain or discomfort during active inflammation	Permanent visual field defects from retinal scarring Chronic retinal atrophy with irreversible vision loss Retinal detachment requiring surgical repair Optic nerve damage causing persistent visual impairment Increased risk of recurrent CMV retinitis in immunocompromised patients

Differential Diagnoses

Retinitis (Cytomegalovirus - HHV-5) versus Toxoplasma gondii Retinitis

Retinitis (Cytomegalovirus - HHV-5)	Toxoplasma gondii Retinitis
Double-stranded DNA virus Cytomegalovirus (HHV-5)	Intracellular protozoan parasite Toxoplasma gondii
Primarily affects immunocompromised patients (e.g., AIDS)	Occurs in immunocompetent and immunocompromised hosts
Diffuse, granular retinal necrosis with hemorrhages and vasculitis	Focal necrotizing retinitis with adjacent old chorioretinal scars
Responds to ganciclovir or valganciclovir	Responds to pyrimethamine and sulfadiazine

Retinitis (Cytomegalovirus - HHV-5) versus Herpes Simplex Virus (HSV) Retinitis

Retinitis (Cytomegalovirus - HHV-5)	Herpes Simplex Virus (HSV) Retinitis
Double-stranded DNA virus Cytomegalovirus (HHV-5)	Double-stranded DNA virus HSV-1 or HSV-2
Slower progression with minimal pain	Rapidly progressive necrotizing retinitis often with pain
PCR positive for CMV DNA in ocular fluid	PCR positive for HSV DNA in ocular fluid
Responds to ganciclovir or valganciclovir	Responds to acyclovir

Retinitis (Cytomegalovirus - HHV-5) versus Syphilitic Uveitis/Retinitis

Retinitis (Cytomegalovirus - HHV-5)	Syphilitic Uveitis/Retinitis
No specific sexual exposure history; positive CMV PCR	History of unprotected sexual contact or positive syphilis serology
Positive CMV PCR in ocular fluid	Positive non-treponemal and treponemal tests (RPR, FTA-ABS)
Progressive necrotizing retinitis with hemorrhages	Variable course with granulomatous inflammation
Responds to ganciclovir or valganciclovir	Responds to intravenous penicillin

Retinitis (Cytomegalovirus - HHV-5) versus Acute Retinal Necrosis (ARN) Syndrome

Retinitis (Cytomegalovirus - HHV-5)	Acute Retinal Necrosis (ARN) Syndrome
Caused by Cytomegalovirus (HHV-5)	Caused by varicella-zoster virus (VZV) or HSV
Slower progression with less vitritis	Rapidly progressive peripheral necrotizing retinitis with severe vitritis
Occurs mainly in immunocompromised hosts	Occurs in immunocompetent hosts
Responds to ganciclovir or valganciclovir	Responds to acyclovir or valacyclovir

Retinitis (Cytomegalovirus - HHV-5) versus HIV Retinopathy

Retinitis (Cytomegalovirus - HHV-5)	HIV Retinopathy
Full-thickness retinal necrosis with hemorrhages	Cotton wool spots and microvascular changes without frank necrosis
Occurs mainly in patients with CD4 count <50 cells/mm3	Occurs in HIV patients regardless of CD4 count
CMV DNA detected by PCR in ocular fluid	No viral DNA detected in ocular fluid
Requires ganciclovir or valganciclovir	No specific antiviral treatment required